All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Shionogi secures $482m BARDA contract to tackle AMR crisis

Japanese pharma company Shionogi has secured a contract worth up to $482m with the US’s Biomedical Advanced Research and Development…
Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic

Sidewinder Therapeutics has secured $137m in a Series B financing round to progress its pipeline of bispecific antibody-drug conjugates (ADCs)…
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout

Biogen has forged a $5.6bn deal to acquire immunology and rare disease specialist Apellis Pharmaceuticals – marking another M&A milestone…
Navigating commercial gaps to supercharge the UK life sciences sector

Off the northwestern coast of mainland Europe, there sits an island with big ambitions for its life sciences sector. Though…
Blackstone closes largest ever private funding investment round at $6.3bn

Private investment platform Blackstone closed a funding raise that has brought in $6.3bn in capital to support its ongoing life…

Eli Lilly and Insilico Medicine forge $2.75bn AI-driven R&D pact

Eli Lilly is joining forces with artificial intelligence (AI)-powered biotech, Insilico Medicine, in a drug discovery and development agreement worth…
Recordati sizes up €10.9bn CVC Capital acquisition offer

Italian pharmaceutical company, Recordati, has confirmed that it’s weighing an acquisition offer from private equity manager, CVC, which is looking…
J&J’s Darzalex nets first self-administered cancer injectable approval

Johnson & Johnson’s (J&J) blockbuster cancer immunotherapy, Darzalex (daratumumab), has secured European approval for self-administration, marking the first time an…
Corcept’s first-in-class ovarian cancer drug gains FDA approval

Corcept Therapeutics has secured US approval for its selective glucocorticoid receptor agonist, Lifyorli (relacorilant), in ovarian cancer more than three…
UCB banks on Georgia for $2bn biologics manufacturing facility

UCB has chosen Georgia as the home for its new biologics manufacturing facility, cementing its legacy in the state and…